WuXi Biologics
Logotype for WuXi Biologics (Cayman) Inc

WuXi Biologics (2269) investor relations material

WuXi Biologics H1 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for WuXi Biologics (Cayman) Inc
H1 2026 earnings summary26 Aug, 2026

Executive summary

  • Revenue grew 18.4% year-over-year to RMB11.8 billion, with constant currency growth at 23.4%, driven by broad-based growth across project stages and geographies.

  • Gross margin expanded to 46.2%, with adjusted gross margin at 48.4%, up 280–350 basis points year-over-year.

  • The company added 169 new integrated projects, bringing the total to over 1,000, with 70%+ of new projects in bi- & multi-specifics and ADCs, and robust project retention above 95%.

  • Portfolio increasingly weighted toward higher-margin ADCs and bispecifics, now over 50% of assets and 55% of revenue.

  • Significant expansion in manufacturing capacity and global footprint, including new facilities in the U.S., Singapore, and China, and strategic acquisitions such as BioDlink and Transcenta's manufacturing facility.

Financial highlights

  • Adjusted EBITDA rose 24.9% to RMB5.4 billion, with margin expanding to 45.6%.

  • Adjusted net profit increased 38.6% year-over-year to RMB3,937.3 million, with margin up to 33.4%; adjusted net profit attributable to owners was RMB3,305.7 million (+38.4%).

  • IFRS net profit grew 5.8% to RMB2,916.2 million; basic EPS up 3.4% to RMB0.60 per share.

  • Free cash flow reached RMB1.5 billion, a record for the first half; available funds stood at RMB13.7 billion as of June 30, 2026.

  • CapEx for H1 was RMB2.8 billion, with full-year 2026 projection at RMB7.1 billion and 2027 at RMB8 billion.

Outlook and guidance

  • FY2026 revenue growth guidance raised to 20–23% in constant currency and 15–18% in RMB terms.

  • Manufacturing revenue CAGR expected at 30% over the next three years, with overall revenue CAGR at 20%.

  • Margin expansion targeted at 100–150 basis points per year.

  • Growth acceleration expected each year through 2028, with manufacturing and biosimilar segments as key drivers.

  • Annual IND filing capacity to expand to 300 by 2027, supporting future growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next WuXi Biologics earnings date

Logotype for WuXi Biologics (Cayman) Inc
H2 202624 Mar, 2027
WuXi Biologics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next WuXi Biologics earnings date

Logotype for WuXi Biologics (Cayman) Inc
H2 202624 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

WuXi Biologics (Cayman) Inc. is a global contract research, development, and manufacturing organization (CRDMO) focused on biologics. The company offers comprehensive services that span from biologic discovery and development to commercial manufacturing. Key offerings include protein generation, antibody development, assay development, and regulatory affairs. The company is headquartered in Wuxi, China, and its shares are listed on the Hong Kong Stock Exchange.